These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 17845681)
1. Infliximab: getting the most for your money. Irving PM; Gibson PR J Gastroenterol Hepatol; 2007 Oct; 22(10):1559-61. PubMed ID: 17845681 [No Abstract] [Full Text] [Related]
2. The real cost of pediatric Crohn's disease: the role of infliximab in the treatment of pediatric IBD. Kay M; Wyllie R Am J Gastroenterol; 2003 Apr; 98(4):717-20. PubMed ID: 12738445 [No Abstract] [Full Text] [Related]
3. Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy. Wan GJ; Kozma CM; Slaton TL; Olson WH; Feagan BG J Med Econ; 2014 Jun; 17(6):384-93. PubMed ID: 24673303 [TBL] [Abstract][Full Text] [Related]
4. Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFalpha reduce colitis-associated colorectal carcinogenesis? Biancone L; Petruzziello C; Calabrese E; Zorzi F; Naccarato P; Onali S; Pallone F Gut; 2009 Dec; 58(12):1703. PubMed ID: 19923350 [No Abstract] [Full Text] [Related]
5. [Infliximab for the management of pyoderma gangrenosum in inflammatory bowel disease: one for all?]. Tanczos BT; Baumgart DC Z Gastroenterol; 2006 Jul; 44(7):609-10. PubMed ID: 16823703 [No Abstract] [Full Text] [Related]
6. A review of infliximab use in ulcerative colitis. Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261 [TBL] [Abstract][Full Text] [Related]
7. Associations between the IGF system and inflammatory markers in inflammatory bowel disease. Grønbaek H; Eivindson MV Aliment Pharmacol Ther; 2006 Feb; 23(4):553-4; author reply 554-5. PubMed ID: 16441476 [No Abstract] [Full Text] [Related]
8. Incorrect cost of infliximab in fistulizing Crohn's disease. Lichtenstein GR Gastroenterology; 2004 Aug; 127(2):691-2; author reply 692-3. PubMed ID: 15300614 [No Abstract] [Full Text] [Related]
10. Evaluation of the drug treatment regimens for inflammatory bowel disease. Brock EM; Zabihollah M Expert Opin Pharmacother; 1999 Nov; 1(1):15-8. PubMed ID: 11249558 [No Abstract] [Full Text] [Related]
11. Interest heats up in gastrointestinal space. Sheridan C Nat Biotechnol; 2006 Jul; 24(7):727-8. PubMed ID: 16841039 [No Abstract] [Full Text] [Related]
12. Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates? Cannom RR; Kaiser AM; Ault GT; Beart RW; Etzioni DA Am Surg; 2009 Oct; 75(10):976-80. PubMed ID: 19886148 [TBL] [Abstract][Full Text] [Related]
13. [Immunobiology of chronic inflammatory bowel diseases]. Siegmund B; Zeitz M Dtsch Med Wochenschr; 2006 Nov; 131(47):2657-60. PubMed ID: 17109275 [No Abstract] [Full Text] [Related]
14. [Biological drugs in inflammatory bowel disease: Management and care]. Guerra I; Bermejo F Rev Esp Enferm Dig; 2015 Jul; 107(7):454. PubMed ID: 26140643 [No Abstract] [Full Text] [Related]
15. Biosimilars: in support of extrapolation of indications. Ebbers HC J Crohns Colitis; 2014 May; 8(5):431-5. PubMed ID: 24594005 [TBL] [Abstract][Full Text] [Related]
16. IBD highlights from the 1999 American College of Gastroenterology meeting: infliximab and 6-MP. Wolf DC Inflamm Bowel Dis; 2000 Feb; 6(1):59-60. PubMed ID: 10701151 [No Abstract] [Full Text] [Related]